Computer-aided diagnosis of prostate cancer based on deep neural networks from multi-parametric magnetic resonance imaging

Revolutionizing prostate cancer therapy: Artificial intelligence - Based nanocarriers for precision diagnosis and treatment

Prostate cancer is one of the major health challenges in the world and needs novel therapeutic approaches to overcome the limitations of conventional treatment. This review delineates the transformative potential of artificial intelligence (AL) in enhancing nanocarrier-based drug delivery systems for prostate cancer therapy. With its ability to optimize nanocarrier design and predict drug delivery kinetics, AI has revolutionized personalized treatment planning in oncology. We discuss how AI can be integrated with nanotechnology to address challenges related to tumor heterogeneity, drug resistance, and systemic toxicity. Emphasis is placed on strong AI-driven advancements in the design of nanocarriers, structural optimization, targeting of ligands, and pharmacokinetics. We also give an overview of how AI can better predict toxicity, reduce costs, and enable personalized medicine. While challenges persist in the way of data accessibility, regulatory hurdles, and interactions with the immune system, future directions based on explainable AI (XAI) models, integration of multimodal data, and green nanocarrier designs promise to move the field forward. Convergence between AI and nanotechnology has been one key step toward safer, more effective, and patient-tailored cancer therapy.

Personalised in silico biomechanical modelling towards the optimisation of high dose-rate brachytherapy planning and treatment against prostate cancer

High dose-rate brachytherapy presents a promising therapeutic avenue for prostate cancer management, involving the temporary implantation of catheters which deliver radioactive sources to the cancerous site. However, as catheters puncture and penetrate the prostate, tissue deformation is evident which may affect the accuracy and efficiency of the treatment. In this work, a data-driven in silico modelling procedure is proposed to simulate brachytherapy while accounting for prostate biomechanics. Comprehensive magnetic resonance and transrectal ultrasound images acquired prior, during and post brachytherapy are employed for model personalisation, while the therapeutic procedure is simulated via sequential insertion of multiple catheters in the prostate gland. The medical imaging data are also employed for model evaluation, thus, demonstrating the potential of the proposed in silico procedure to be utilised pre- and intra-operatively in the clinical setting.

A mixed Mamba U-net for prostate segmentation in MR images

The diagnosis of early prostate cancer depends on the accurate segmentation of prostate regions in magnetic resonance imaging (MRI). However, this segmentation task is challenging due to the particularities of prostate MR images themselves and the limitations of existing methods. To address these issues, we propose a U-shaped encoder-decoder network MM-UNet based on Mamba and CNN for prostate segmentation in MR images. Specifically, we first proposed an adaptive feature fusion module based on channel attention guidance to achieve effective fusion between adjacent hierarchical features and suppress the interference of background noise. Secondly, we propose a global context-aware module based on Mamba, which has strong long-range modeling capabilities and linear complexity, to capture global context information in images. Finally, we propose a multi-scale anisotropic convolution module based on the principle of parallel multi-scale anisotropic convolution blocks and 3D convolution decomposition. Experimental results on two public prostate MR image segmentation datasets demonstrate that the proposed method outperforms competing models in terms of prostate segmentation performance and achieves state-of-the-art performance. In future work, we intend to enhance the model's robustness and extend its applicability to additional medical image segmentation tasks.

Comprehensive Assessment of MRI-based Artificial Intelligence Frameworks Performance in the Detection, Segmentation, and Classification of Prostate Lesions Using Open-Source Databases

Numerous MRI-based artificial intelligence (AI) frameworks have been designed for prostate cancer lesion detection, segmentation, and classification via MRI as a result of intrareader and interreader variability that is inherent to traditional interpretation. Open-source data sets have been released with the intention of providing freely available MRIs for the testing of diverse AI frameworks in automated or semiautomated tasks. Here, an in-depth assessment of the performance of MRI-based AI frameworks for detecting, segmenting, and classifying prostate lesions using open-source databases was performed. Among 17 data sets, 12 were specific to prostate cancer detection/classification, with 52 studies meeting the inclusion criteria.

Research related to the diagnosis of prostate cancer based on machine learning medical images: A review

BACKGROUND

Prostate cancer is currently the second most prevalent cancer among men. Accurate diagnosis of prostate cancer can provide effective treatment for patients and greatly reduce mortality. The current medical imaging tools for screening prostate cancer are mainly MRI, CT and ultrasound. In the past 20 years, these medical imaging methods have made great progress with machine learning, especially the rise of deep learning has led to a wider application of artificial intelligence in the use of image-assisted diagnosis of prostate cancer.

METHOD

This review collected medical image processing methods, prostate and prostate cancer on MR images, CT images, and ultrasound images through search engines such as web of science, PubMed, and Google Scholar, including image pre-processing methods, segmentation of prostate gland on medical images, registration between prostate gland on different modal images, detection of prostate cancer lesions on the prostate.

CONCLUSION

Through these collated papers, it is found that the current research on the diagnosis and staging of prostate cancer using machine learning and deep learning is in its infancy, and most of the existing studies are on the diagnosis of prostate cancer and classification of lesions, and the accuracy is low, with the best results having an accuracy of less than 0.95. There are fewer studies on staging. The research is mainly focused on MR images and much less on CT images, ultrasound images.

DISCUSSION

Machine learning and deep learning combined with medical imaging have a broad application prospect for the diagnosis and staging of prostate cancer, but the research in this area still has more room for development.

Deep-learning prostate cancer detection and segmentation on biparametric versus multiparametric magnetic resonance imaging: Added value of dynamic contrast-enhanced imaging

OBJECTIVES

To develop diagnostic algorithms of multisequence prostate magnetic resonance imaging for cancer detection and segmentation using deep learning and explore values of dynamic contrast-enhanced imaging in multiparametric imaging, compared with biparametric imaging.

METHODS

We collected 3227 multiparametric imaging sets from 332 patients, including 218 cancer patients (291 biopsy-proven foci) and 114 noncancer patients. Diagnostic algorithms of T2-weighted, T2-weighted plus dynamic contrast-enhanced, biparametric, and multiparametric imaging were built using 2578 sets, and their performance for clinically significant cancer was evaluated using 649 sets.

RESULTS

Biparametric and multiparametric imaging had following region-based performance: sensitivity of 71.9% and 74.8% (p = 0.394) and positive predictive value of 61.3% and 74.8% (p = 0.013), respectively. In side-specific analyses of cancer images, the specificity was 72.6% and 89.5% (p < 0.001) and the negative predictive value was 78.9% and 83.5% (p = 0.364), respectively. False-negative cancer on multiparametric imaging was smaller (p = 0.002) and more dominant with grade group ≤2 (p = 0.028) than true positive foci. In the peripheral zone, false-positive regions on biparametric imaging turned out to be true negative on multiparametric imaging more frequently compared with the transition zone (78.3% vs. 47.2%, p = 0.018). In contrast, T2-weighted plus dynamic contrast-enhanced imaging had lower specificity than T2-weighted imaging (41.1% vs. 51.6%, p = 0.042).

CONCLUSIONS

When using deep learning, multiparametric imaging provides superior performance to biparametric imaging in the specificity and positive predictive value, especially in the peripheral zone. Dynamic contrast-enhanced imaging helps reduce overdiagnosis in multiparametric imaging.

Equilibrium Optimization Algorithm with Deep Learning Enabled Prostate Cancer Detection on MRI Images

The enlargement of the prostate gland in the reproductive system of males is considered a form of prostate cancer (PrC). The survival rate is considerably improved with earlier diagnosis of cancer; thus, timely intervention should be administered. In this study, a new automatic approach combining several deep learning (DL) techniques was introduced to detect PrC from MRI and ultrasound (US) images. Furthermore, the presented method describes why a certain decision was made given the input MRI or US images. Many pretrained custom-developed layers were added to the pretrained model and employed in the dataset. The study presents an Equilibrium Optimization Algorithm with Deep Learning-based Prostate Cancer Detection and Classification (EOADL-PCDC) technique on MRIs. The main goal of the EOADL-PCDC method lies in the detection and classification of PrC. To achieve this, the EOADL-PCDC technique applies image preprocessing to improve the image quality. In addition, the EOADL-PCDC technique follows the CapsNet (capsule network) model for the feature extraction model. The EOA is based on hyperparameter tuning used to increase the efficiency of CapsNet. The EOADL-PCDC algorithm makes use of the stacked bidirectional long short-term memory (SBiLSTM) model for prostate cancer classification. A comprehensive set of simulations of the EOADL-PCDC algorithm was tested on the benchmark MRI dataset. The experimental outcome revealed the superior performance of the EOADL-PCDC approach over existing methods in terms of different metrics.